Prediction BioSciences

Executive Summary

Prediction BioSciences is a clinical-stage biotechnology company based in Lyon, France, dedicated to discovering and developing innovative therapeutics and diagnostics for stroke and neurodegenerative diseases. The company's proprietary platform integrates plasma-based diagnostics, engineered exosomes, and cell-type specific brain targets to enable early detection and targeted treatment. Founded in 2016, Prediction BioSciences operates through collaborative partnerships and has secured support from public agencies such as the French National Research Agency. Its approach aims to address critical unmet needs in neurological disorders, where early diagnosis and effective therapies remain limited. The company is privately held and has not disclosed financial details or pipeline specifics. Despite the lack of publicly available data on its lead programs, Prediction BioSciences' technology holds potential for significant impact in neurology. However, the company faces typical biotech risks including clinical trial failures, regulatory hurdles, and competition from larger players. Its reliance on partnerships and public funding underscores a need for strategic collaborations to advance its platform. Overall, Prediction BioSciences represents an early-stage opportunity in the neurology diagnostics and therapeutics space, with its innovative exosome-based technology as a key differentiator, but conviction is tempered by limited visibility into its pipeline and financial position.

Upcoming Catalysts (preview)

• H2 2026Phase 1/2 clinical data readout for lead stroke diagnostic candidate35% success
• Q3 2026New public grant from French National Research Agency (ANR) for exosome-based therapy70% success
• H1 2027Strategic partnership with pharmaceutical company for exosome delivery platform40% success